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We investigated the presence of OprD mutations in 60 strains of metallo-ß-lactamase-negative Pseudomonas aeruginosa inter-
mediately susceptible (IS [n 12]; MIC 8g/ml) or susceptible (S [n 48]; MICs < 1 to 4g/ml) to imipenem and/or mero-
penem that were isolated from patients with bacteremia in order to evaluate their impact on carbapenem susceptibility profiles.
The presence of mutations in oprD was detected by sequencing analysis. OprD expression was assessed by both outer membrane
protein (OMP) analysis and real-time PCR (RT-PCR). Fourteen (23%) isolates had an OprD identical to that of PAO1, and OprD
modifications were detected in 46 isolates (77%). Isolates were classified as OprD “full-length types” (T1 [n 40, including both
wild-type OprD and variants showing several polymorphisms]) and OprD “deficient types” (T2 [n 3 for OprD frameshift mu-
tations] and T3 [n 17 for premature stop codons in oprD]). RT-PCR showed that 5 OprD type T1 isolates presented reduced
transcription of oprD (0.1- to 0.4-fold compared to PAO1), while oprD levels increased more than 2-fold over that seen with
PAO1 in 4 OprD type T1 isolates. A total of 50% of the isolates belonging to OprD “deficient types” were susceptible to both car-
bapenems, and 40% were susceptible to meropenem and intermediately susceptible to imipenem. Only one isolate (5%) within
this group was intermediately susceptible to both carbapenems, and one (5%) was susceptible to imipenem and intermediately
susceptible to meropenem. We concluded that OprD inactivating mutations in clinical isolates of P. aeruginosa are not re-
stricted only to carbapenem-resistant isolates but are also found in isolates with imipenem or meropenem MICs of only 0.06 to 4
g/ml.
Pseudomonas aeruginosa has become an important and fre-quent opportunistic nosocomial pathogen. This organism is
characterized by an innate resistance tomultiple classes of antimi-
crobials (12), causing difficult-to-treat infections, which are
therefore associatedwith significantmorbidity andmortality (28).
The broad-spectrum resistance of P. aeruginosa is mainly due
to a combination of different factors: (i) low outer membrane
permeability (27), (ii) the presence of the inducible AmpC
chromosomal ß-lactamase (19, 20), (iii) synergistic action of sev-
eral multidrug efflux systems (32, 33), and (iv) the prevalence of
transferable resistance determinants, in particular, carbapenem-
hydrolyzing enzymes (mainly metallo-ß-lactamases [MBLs])
(11).
Among the several mutation-mediated resistance mechanisms
existing in P. aeruginosa are those conferring decreased suscepti-
bility or resistance to carbapenems. These antimicrobial agents are
commonly used to treat infections produced by multiresistant
strains of P. aeruginosa, as they are stable against most clinically
relevant ß-lactamases (including broad-spectrum, extended-
spectrum, and AmpC-type enzymes). Carbapenems exert their
action primarily by inhibiting the peptidoglycan-assembling
transpeptidases (penicillin-binding proteins [PBP]) located on
the outer face of the cytoplasmic membrane. In general, carbap-
enems can efficiently cross the outer membrane of the bacterium,
as they are small hydrophilic antibiotics. They enter the cell by
passing through the aqueous channels provided by porin proteins.
The main porin for uptake of carbapenems in P. aeruginosa is the
outer membrane protein (OMP) OprD, a specialized porin which
has a specific role in the uptake of positively charged amino acids
such as lysine and glutamate (14). Other routes for carbapenem
uptake have been proposed (29), but their actual relevance has not
been consistently proved.
Inactivating mutations in OprD have been documented to
confer resistance to imipenem and to a lesser extent to mero-
penem and doripenem (8, 10, 11, 30, 34, 35, 39, 43). It is also
remarkable that mutations leading to the upregulation of the
MexAB-OprM active efflux system may increase the resistance to
meropenem and doripenem but with no effect on the susceptibil-
ity of P. aeruginosa to imipenem, which is not a substrate for this
system (16). Additionally, other resistance-nodulation-cell divi-
sion (RND) efflux systems such as MexCD-OprJ and MexXY-
OprM were previously suggested to be involved in reduced sus-
ceptibility to meropenem (1, 23, 24, 44); nevertheless, their
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implication in carbapenem resistance remains still uncertain. A
recent study suggested that OprD inactivation combined with
AmpCoverexpressionwas themost relevantmechanism to confer
resistance to doripenem in clinical isolates and laboratory mu-
tants of P. aeruginosa (35).
Less frequently, downregulation of oprD can happen in the
so-called nfxCmutants, in which MexEF-OprN is overexpressed.
This coregulation is mediated byMexT, a positive regulator of the
efflux system MexEF-OprN, which also downregulates OprD at
the transcriptional and posttranscriptional levels. This phenotype
is sometimes selected by quinolones but rarely by carbapenems
(17). There are a few studies suggesting a role of the penicillin-
binding proteins (PBPs) in acquired resistance to carbapenems (2,
13, 45). Carbapenem resistance can also arise from production of
MBLs, but this mechanism is a less commonly found mechanism
than the mutation-driven resistance mechanisms (4).
Regardless of the fact that efflux system upregulation, consti-
tutive AmpC hyperproduction, and OprD alterations have been
well described as carbapenem resistance mechanisms in labora-
tory mutants, there is still little information on how these mech-
anisms interplay in clinical isolates of P. aeruginosa, particularly in
those presenting a low level of resistance. A recent study has ad-
dressed the issue of how the carbapenem resistance patterns ob-
served in clinical isolates ofP. aeruginosa are not fully explained by
some of the aforementioned mechanisms (8).
In this study, we have analyzed the alterations of OprD in a
number of clinical isolates of P. aeruginosa with different carbap-
enem susceptibility profiles, ranging from susceptible to interme-
diately susceptible. Sequence and computerized structure analyses
of OprD were carried out in order to correlate inactivating muta-
tions and othermechanismswith the resistance patterns observed.
The presence of additional mechanisms involved in carbapenem
resistance in clinical isolates of P. aeruginosawas also investigated.
MATERIALS AND METHODS
Selection of bacterial strains. A total of 60 nonduplicate clinical isolates
of metallo-ß-lactamase-negative P. aeruginosawith different carbapenem
susceptibility profiles, ranging from susceptible to intermediately suscep-
tible, were included in this study. These isolates were selected from a
collection of 190 strains previously studied that were recovered from
bloodstream infections in a Spanishmulticenter study carried out in 2008,
for which OprD analysis had been carried out in 25 imipenem-resistant
strains (MIC 8 mg/liter) (4).
P. aeruginosa strains PA-14 and PAO1 and two PAO1-derived mutants,
PA3047 (hyperproducingAmpC) from theP. aeruginosa transposonmutant
collection of theUniversity ofWashington (Seattle,WA) and PAO45 (OprD
deficient) (42),were also included in the study.MICsof antibiotics other than
carbapenems and expression levels of the genes encoding the chromosomal
-lactamase AmpC (ampC) protein and the four major P. aeruginosa efflux
pump systems, MexAB-OprM (mexB), MexXY-OprM (mexY), MexCD-
OprJ (mexD), andMexEF-OprN (mexF), were determined in the 60 clinical
isolates in comparison to the wild-type PAO1 strain by real-time PCR (RT-
PCR) in a previous work (4).
Molecular typing and antimicrobial susceptibility testing of clinical
isolates. Clonal relatedness was evaluated through pulsed-field gel elec-
trophoresis (PFGE) analysis following previously described protocols
(38). The PFGEprofileswere analyzed according to the criteria of Tenover
et al. (41).
The MICs of imipenem and meropenem were determined by broth
microdilution as described before (4). For some strains, the MICs of imi-
penem and/or meropenem were also determined by Etest (bioMérieux,
Marcy l’Etoile, France) as described by themanufacturer. In all cases,MIC
breakpoints were those defined by CLSI (5).
Carbapenem hydrolysis assay. Carbapenemase activity in crude son-
icated bacterial extracts was quantified in a spectrophotometer, according
to previously described protocols (18), with slight modifications. Briefly,
reactionswere performed in 1ml of 50mMassay buffer (AB) consisting of
HEPES (pH7.0) supplementedwith 5MZnSO4 (Sigma,Madrid, Spain)
at 25°C. Hydrolysis of both imipenem and meropenem was monitored at
300 and 297 nm, respectively, using an initial substrate concentration of
150 M. P. aeruginosa strains COL-1 (VIM-2-producing strain) (31) and
PAO1 were used as positive and negative controls, respectively.
DNA sequencing and computer analyses of sequence data.The pres-
ence of inactivating mutations in oprD was investigated in all the isolates
through PCR amplification of the entire gene and its upstream flanking
region, containing the promoter, and downstream of the structural gene
with specific primers, OprD_FlankF and OprD_FlankR. These primers
and two additional pairs of oligonucleotides that were previously de-
scribed (36) were employed for sequencing of oprD. The mexT gene was
also sequenced in those strains showing high expression levels of mexF.
The primers used for this purpose are listed inTable 1. PCR amplifications
were conducted in a total volume of 50 l containing 0.25 mM deoxy-
nucleoside triphosphates (dNTPs), 1 mM MgCl2, 0.2 M each primer, 2
U of AmpliTaq Gold DNA polymerase (Applied Biosystems), and 500 ng
of template DNA. PCR conditions were as follows: 95°C for 5 min and 30
TABLE 1 Primers used in this study
Gene Primer name Sequence 5=–3= Source or reference Use
oprD OprD_FlankF CGGCTGAGGGGAAAGTCGCC This study Sequencing of oprD
OprD_FlankR TACGCGGTCATTCTCGGGCG
OprD.F GGAACCTCAACTATCGCCAAG 36
OprD.R GTTGCCTGTCGGTCGATTAC
OprD2.F ACTTCACCGAGGGCAAGG
OprD2.R CAGAGTTGGCGAGGAAAATC
RTiOprD_F GGTTTCCGCAGGTAGCACTCAGT This study Real-time PCR
RTiOprD_R AAGCCGGATTCATAGGTGGTGAG
proC ProC_for CCTGCTCCACCAGTGCTT 25
ProC_rev CTGTCCAGCGAGGTCGAG
mexT MexT_F1 CATCAGCACCACGTCGCCAT This study Sequencing ofmexT
MexT_R1 ACTTCGGCGACGCTGACCTT
MexT_F2 CGCGAGCCCAGGAAATCTTC
MexT_R2 TAGCTGACGCCCACCGAGAT
Ocampo-Sosa et al.
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cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 2 min. For each gene,
DNA sequences on both strands were determined by using an external
resource (Macrogen Inc., Seoul, South Korea). Computer analysis of the
DNA sequence data was performed with Vector NTI Advance version
9.0.0 software (InforMax; Invitrogen). Protein alignments were carried
out using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). In ev-
ery case, both the nucleotide and the amino acid sequences were com-
pared between the clinical isolates, the PAO1 reference strain, strains
PA14 (GenBank accession no. ABJ10119), PA7 (accession no.
YP_001349899), LESB58 (accession no. YP_002441940), andMFY72 (ac-
cession no. CAL23856), and clinical isolates 59 and 120, two imipenem-
resistant strains analyzed in a previous study (4). OprD secondary struc-
tures were compared to the one reported by Biswas et al. (3), deposited in
the Protein Data Bank (http://www.pdb.org) under accession code 2ODJ,
and visualized by using the ESPript 2.0 software (http://espript.ibcp.fr
/ESPript/ESPript/). Images of OprD tridimensional (3D) structures were
represented using PyMol (http://www.pymol.org/).
OMP analysis.Cultures ofP. aeruginosawere grownovernight at 37°C
in 5 ml of Mueller-Hinton Broth medium (Difco/Becton Dickinson,
Sparks, MD) and then diluted 100-fold into fresh medium. Bacterial cells
were incubated for approximately 5 h with shaking at 37°C to yield late-
logarithmic-phase cells. Outer membrane protein (OMP) profiles were
examined using a previously reported method (26). OMPs were run on
standard 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels and
stained with Coomassie blue. OprD profiles from clinical isolates were
compared with those of the PAO1 reference strain and PAO45.
Quantification of oprD expression by RT-PCR. The levels of expres-
sion of the oprD gene were determined by real-time PCR (RT-PCR) in a
selection of isolates. Primers used for RT-PCR are listed inTable 1. Briefly,
strains were grown in 10ml of LB broth at 37°C and 180 rpm to the late log
phase (optical density at 600 nm [OD600]  0.8 to 1) and collected by
centrifugation. Total RNA was extracted with an SV Total RNA isolation
system (Promega,Madison,WI), according to themanufacturer’s recom-
mendations. DNAwas removed with RNase-Free DNase treatment (Am-
bion, Austin, TX), and RNA preparations were tested for the lack of DNA
contamination by RT-PCR with primers specific for the proC gene (25).
None of the RNA samples used in the study amplified before cycle 35.
RNA concentrations were determined in a spectrophotometer (Nano-
Drop 1000; Thermo Scientific, Wilmington, DE), and the quality of the
samples was checked in agarose gels under denatured conditions. Quan-
tification of the oprD gene was performed by quantitative PCR (qPCR)
using two-step reverse transcription- and RT-PCR and an iScript cDNA
synthesis kit (Bio-Rad) and SYBR Premix Ex Taq (TaKaRa). The proC
gene was used as an internal reference to normalize the relative amount of
RNA (25). The experiment was repeated in triplicate, using independent
RNA extractions in every assay. The expression of the oprD gene in each
isolate was compared to its expression in the PAO1 reference strain. The
genes were considered to be up- or downregulated when the amounts of
RNA were at least 2 times higher- or lower than those in the reference
strain.
RESULTS AND DISCUSSION
Loss of OprD from the outer membranes is one of the most im-
portant mechanisms of resistance to carbapenems in P. aerugi-
nosa. Multiple studies have evaluated the importance of OprD
alterations in laboratory and clinical isolates of P. aeruginosa re-
sistant to carbapenems.However, there is little information on the
relevance of this mechanism in intermediately susceptible isolates
or with MICs near the breakpoints for susceptibility. Dib et al.
studied the implications of loss of OprD and its association with
decreases in susceptibility to carbapenems in a collection of 89
clinical isolates ofP. aeruginosa (6). Those authors demonstrated a
correlation between the levels of expression of OprD and the de-
grees of susceptibility to imipenem. Nevertheless, they detected
decreased expression of OprD in some strains showing imipenem
MICs of 2 to 4 g/ml. Subsequent studies have also assessed the
relationship between OprD expression and carbapenem suscepti-
bility profiles in clinical strains of P. aeruginosa. El Amin et al.
TABLE 2 Prevalence of OprD types among the clinical isolates of Pseudomonas aeruginosa showing different carbapenem resistance phenotypes
contrasted to overexpression of AmpC ß-lactamase and efflux pump systems
Resistance phenotype
(g/ml)a
Total no. of
strains (%)
No. of isolates within indicated
OprD typeb (%) No. of isolates showing overexpression of indicated product (%)
T1 T2 T3 AmpC MexB MexY MexF MexD Othersc
All 60 (100) 40 (68) 3 (5) 17 (28) 11 (18) 4 (7) 5 (8) 4 (7) 0 6 (10)
Group 1
IIS-MIS 1 (2) 0 0 1 (100) 1 (100) 0 0 1 (100) 0 1d (100)
Group 2
IIS-MS 9 (15) 1 (33) 0 8 (89) 0 0 1 (11) 1 (11) 0 0
Group 3
IS-MIS 2 (3) 1 (50) 1 (50) 0 1 (50) 1 (50) 1 (50) 1 (50) 0 1d, 1e (100)
Group 4
IS-MS 48 (80) 38 (79) 2 (4) 8 (17) 9 (19) 3 (6) 3 (6) 1 (2) 0 3 (6)
Subgroups 48 (80) 38 (79) 2 (4) 8 (17) 9 (19) 3 (6) 3 (6) 1 (2) 0 3 (6)
IS (1)-MS (1) 16 (27) 14 (87) 1 (7) 1 (6) 4 (25) 0 0 0 0 0
IS (2–4)-MS (2–4) 9 (15) 7 (78) 1 (11) 1(11) 2 (22) 1 (11) 0 0 0 1f
IS (1)-MS (2–4) 3 (5) 3 (100) 0 0 0 2 (67) 1 (33) 1 (33) 0 1e, 1g (33)
IS (2–4)-MS (1) 20 (33) 14 (70) 0 6 (30) 3 (15) 0 2 (10) 0 0 0
a I, imipenem; M, meropenem; R, resistant; IS, intermediately susceptible; S, susceptible.
b Classification is indicated according to the type of mutation present in oprD and OprD as follows: T1, full-length type (including wild-type OprD and OprD variants showing
several polymorphisms in the amino acid sequence); T2 and T3, “deficient types” (i.e., mutations result in earlier termination of translation); T2, premature stop codon, T3,
frameshift mutation due to insertions or deletions.
c “Other”data represent combinations of different resistance mechanisms as indicated.
d AmpC and MexF resistance mechanisms.
e MexB and MexY resistance mechanisms.
f AmpC and MexB resistance mechanisms.
g MexB and MexF resistance mechanisms.
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TABLE 3 Different OprD types found among the 60 clinical isolates of P. aeruginosa
OprD
type(s)a
No. of
isolates
Resistance
phenotype(s)
(no. of isolates)b
OprD type
classification Alteration(s) or mutation(s)j
Effect or OprD
structure(s)
affected
T1 Full-length type
T1-I 14 IS-MS (13), IIS-MS (1) Wild type None None
T1-Ia 1 IS-MS Substitution of 1
amino acid residue
L440P None
T1-II 4 IS-MS (4) Several polymorphisms T103S, K115T, F170L L4
i, L6
T1-IIa 1 IS-MS D43N, T103S, K115T, F170L L4, L6
T1-IIb 1 IS-MS V82L, T103S, K115T, F170L L4, L6
T1-III 1 IS-MS T103S, K115T, F170L, Y438L, P439S, L440A, S441V,
I442D, L443P, 44353
c
L4, L6 C-terminal
extreme
T1-IIIa 1 IS-MIS T103S, K115T, F170L, Y438L, P439S, L440A, S441V,
I442D, L443P, 44352
d
L4, L6 C-terminal
extreme
T1-IV 3 IS-MS T103S, K115T, F170L, E185Q, P186G, V189T, R310E,
A315G, G425A
L4, L6, L13
T1-IVa 1 IS-MS T103S, K115T, F170L, E185Q, P186G, V189T, R310E,
A315G, G425A, S441K
L4, L6, L13
T1-IVb 1 IS-MS T103S, K115T, F170L, E185Q, P186G, V189T, R310E,
A315G, G425A, Y438S
L4, L6, L13
T1-V 1 IS-MS Several polymorphisms T103S, K115T, F170L, E185Q, P186G, V189T, R310E,
A315G, G425A, L440T, S441V, I442D, L443P, 44357
e
L4, L6, L13
C-terminal
extreme
T1-VI 9 IS-MS D43N, S57E, S59R, E202Q, I210A, E230K, S240T, N262T,
A267S, A281G, K296Q, Q301E, R310G, V359L,372
(VDSSSS-YAGL-)383
f
L2, L7, L8, L9,
L15
T1-VIa 1 IS-MS D43N, S57E, S59R, E202Q, I210A, E230K, S240T, N262T,
A267S, A281G, K296Q, Q301E, R310G, V359L, 372(VD
SSSS-YAGL-)383, Y438V, P439S
L1, L7, L8, L9,
L15
T1-VII 1 IS-MS S57E, S59R, V127L, E185Q, V189T, E202Q, I210A, E230K,
S240T, N262T, T276A, A281G, K296Q, Q301E, R310E,
A315G, L374M, 372(VDSSSS-YAGL)383, S403A,
Q424E, D437E
L1, L4, L5, L7, 15
T2, T3 Porin-deficient types
T2 Premature stop codon Loss of porin
2 IS-MS nt 180GGA¡TGA
1 IS-MIS nt 424CAA¡TAA
T3 Frame shift mutations
due to insertions or
deletions
Loss of porin
1 IIS-MS nt 22Gnt 23
g
1 IIS-MS nt 64Cnt 65
1 IS-MS nt 66Tnt 67
1 IIS-MS nt 157Cnt 158
1 IIS-MS nt 368Ant 369
1 IIS-MIS nt 934Tnt 935
1 IS-MS nt 936CGTAnt 937
6 IS-MS (4), IIS-MS (2) nt 939Cnt 940
1 IIS-MS nt 392C
2 IS-MS, IIS-MS nt 1295T
h
1 IS-MS nt 1297C
h
a OprD type T1 has been divided in 7 subtypes based on the amino acid pattern alterations.
b Numbers in parentheses represent numbers of strain showing a determined resistance phenotype.
c This OprD type has 53 additional amino acids residues at its C-terminal region.
d This OprD type has 52 additional amino acids residues at its C-terminal region.
e This OprD type has 57 additional amino acids residues at its C-terminal region.
f Divergent sequence of 10 amino acid residues previously reported by Epp et al. (9).
g This OprD lacks 20 amino acid residues at the start of its N-terminal region.
h The isolates have a deletion of 10 amino acid residues from position 434(LIVDYPLSIL)443.
i “L” designates any of the OprD loops possibly affected by a determined amino acid substitution.
j Underlining indicates the nucleotide that changes.
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evaluated the expression of oprD among clinical isolates of P.
aeruginosa and found significant reduction of oprD transcription
in 5 susceptible and 5 intermediately susceptible strains (8).
With this study, we aimed to gain an insight into the relation-
ship between OprD alterations and/or expression levels and car-
bapenem susceptibility profiles in carbapenem-intermediate and
-susceptible clinical strains of P. aeruginosa. We analyzed the im-
pact of OprD alterations in 60 clinical isolates of metallo-ß-lacta-
mase-negative P. aeruginosa, many of them with carbapenem
MICs close to the susceptible breakpoints. These isolates belonged
to a well-characterized collection of 190 P. aeruginosa strains from
which all the carbapenem resistance mechanisms known so far
were previously evaluated (4). Selection of the isolates was based
on their carbapenem susceptibility profiles, including organisms
with a broad range of susceptibility: susceptible (MICs  1 to 4
g/ml) or intermediately susceptible (MIC  8 g/ml) to both
imipenem and meropenem. The evaluation of the alterations and
mutations found in OprD of clinical strains was complemented
with the analysis of the OprD secondary structure based on the
PAO1 OprD crystal structure recently published (3).
High clonal diversity was observed among the 60 isolates, with
54 different PFGE patterns (see Table S1 in the supplemental ma-
terial). The 60 clinical isolates of P. aeruginosa analyzed in this
study were divided in 4 groups (and 4 subgroups within the group
of isolates susceptible to both imipenem and meropenem) based
on carbapenem sensitivity patterns (Table 1; see also Table S1 in
the supplemental material). Fifty clinical isolates (83%) showed
susceptibility to imipenem and 57 (95%) tomeropenem. Ten iso-
lates (17%) were intermediately susceptible to imipenem and 3
isolates (5%) to meropenem. No carbapenemase activity was
found among the 60 isolates studied, as confirmed by the carbap-
enem hydrolysis assay (data not shown).
Sequencing of the entire oprD gene and its putative promoter
regions permitted analysis of the alterations in OprD in such
strains. Most of the isolates presented point mutations consisting
of single nucleotide deletions or nucleotide substitutions between
positions 62 and 72 (relative to the ATG start codon). Such
mutationswere observed in both susceptible and resistant isolates;
therefore, we considered their involvement in decreased carbap-
enem susceptibility not relevant.
Classification of the isolates in 3 major types (T1, T2, and T3)
was established based on the pattern of alterations or mutations
found inOprD (Tables 2 and 3). TheOprD type T1 grouped those
isolates showing “full-length type” OprD. This type was subdi-
vided in 7 groups, comprising those isolates showing a wild-type
PAO1 OprD and several OprD allelic variants, due to amino acid
substitutions. The OprD types T2 and T3 were called “deficient
types,” as theirmutations resulted in loss of porin as confirmed by
analysis of their OMP profiles (representative results are shown in
Fig. 1). The OprD type T2 designates the porin type in which the
substitution of a nucleotide in the oprD gene resulted in a prema-
ture termination of translation, whereas type T3 comprises those
oprD genes harboring a frameshift mutation due to nucleotide
insertions or deletions.
The analysis of the predicted amino acid sequences of the 40
isolates belonging to OprD type T1 revealed that they were highly
conserved compared to the sequence of PAO1 OprD. Using the
information from the solved X-ray crystal structure of OprD (3)
(rather than the indirect structural details used in other studies),
we have observed that the less conserved regions within OprD
among the clinical strains were those corresponding to the loops
connecting the transmembrane strands (Fig. 2). Fourteen isolates
within this group showed an OprD sequence identical to that of
OprD of PAO1. Following the usual pattern, most of the OprD
full-length type isolates were susceptible strains. Nevertheless, iso-
late SPME 241, displaying an OprD identical to the PAO1 OprD,
had imipenem and meropenem MICs of 8 and 1 g/ml, respec-
tively. This isolate showed a 10.1-fold increase inMexY expression
compared to PAO1. It has been previously suggested that in-
creased transcription levels of MexXY-OprM up to 10-fold may
FIG 1 Analysis of P. aeruginosa outer membrane proteins (OMPs) in a selection of clinical strains with different OprD types. OMPs were run in a 12% SDS
polyacrylamide gel. Lanes M: Precision Plus protein standards (Bio-Rad). OMP profiles of clinical strains were compared to those of PAO1 and PAO45, an
OprD-deficient mutant. Strain numbers are shown above the lanes. OprD types are indicated below the lanes. The black arrowhead indicates the PAO1 OprD
band.
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affect the susceptibility tomeropenembut not to imipenem (7, 34,
44). However, meropenem susceptibility was not altered in this
strain. These results seem to be contradictory, and additional
studies are warranted to evaluate the actual contribution of in-
creased MexY expression to the carbapenem susceptibility of iso-
late SPME 241.
Several OprD allelic variants compared to PAO1 OprD were
found among the 26 remainingOprD sequences belonging to type
T1 (Fig. 2, Table 3). The most frequent amino acid substitutions
were T103S, K115T, and F170L, found in 13 susceptible isolates and
in the PA14 reference strain, which was also susceptible to both
carbapenems. OprD variants showing these amino acid substitu-
tions in loops L3 and L5, initially designated loops L2 and L3 by
Huang et al. (14), were described before in clinical isolates of P.
aeruginosa (8, 11, 37). Other frequently found amino acid substi-
tutions are shown in Table 3; some of them were previously de-
scribed in isolates with different susceptibility profiles to imi-
penem (8). OprD types T1-VI, -VIa, and -VII also showed a
stretch of 12 amino acid residues located in loop L15 (formerly
loop L7) replaced by a sequence of 10 amino acid residues (372-V
DSSSSYAGL-384). P. aeruginosa strains PA7 and LESB58, both
susceptible to carbapenems, also presented this feature (Fig. 2).
Shortening of loop L15 (L1510) was first described by Epp et al.,
who proposed its implication in meropenem uptake, as deletions
in this loop resulted in a 4-fold decrease of the MIC of mero-
penem, presumably due to an opening of the OprD channel al-
lowing optimal penetration of this agent (9). This conclusionmay
be supported by our findings, as all the isolates harboring this
OprD alteration were susceptible to both carbapenems. The L1510
feature has also been previously reported in OprD of clinical iso-
lates from different geographical areas (37, 39). A replacement of
a glutamine (Q) by a glutamate (E) residue at position 301 in loop
L13 (formerly loop L5) was found in isolates with the shortened
L15 loop. It has been suggested that OprD loops L13, L15, and L16
(formerly loop L8)may contribute to the constriction of theOprD
channel opening (9).
The differences in the sequences of some OprD loops do not
seem to affect the pore constriction, as their function is only to
connect the ß-transmembrane domains. Most of the amino acid
substitutions observed in OprD were conserved mutations con-
sisting of changes of one hydrophobic residue to another that was
also hydrophobic, generally located in loops connecting the ß-
sheets or within the ß-sheets with side chains that point to the
outside the ß-barrel. It is expected that such substitutions would
not affect the integrity of the porin.
The replacement of an aspartic (D) residue by an asparagine
(N) at position 43 was found in 11 isolates, 10 of them having the
L1510. This alterationmay result in a change of pore specificity and
conformation, as it consists of a replacement of a positively
charged amino acid (Asp) by a neutral-polarity amino acid (Asn).
Such an amino acid change was described earlier in clinical strains
showing reduced susceptibility to imipenem (8) or resistance to
both carbapenems (39), raising the hypothesis of its association
with resistance to these agents. However, all the isolates that we
found in this study harboring this alteration were susceptible
strains; therefore, we concluded that such a change may not itself
be involved in carbapenem resistance.
Another interesting finding was the presence of 3 isolates,
SPME 32 (type T1-V), SPME 69 (type T1-III), and SPME 205
(type T1-IIIa), that seem to be new allelic variants of OprD not
described before. These isolates have an extended tail of over 50
amino acid residues at the C terminus that provides an additional
membrane-spanning stretch (Fig. 2, Table 3). Isolate SPME32was
susceptible to both carbapenems (MICs of imipenem and mero-
penem, 1 mg/liter and 0.25 mg/liter) and expressed OprD, as
shown by OMP profile analysis (Fig. 1). The oprD mRNA tran-
scription levels of strain SPME 32 were similar to that of PAO1
(0.89-fold). The analysis of OMP profiles showed that isolate
SPME 69 seemed to express OprD. However, the oprD mRNA
expression levels in this strain were reduced in comparison with
PAO1 (0.42-fold). Although isolate SPME 69 showed overexpres-
sion of AmpC (296.6-fold compared to PAO1) and MexB (3.4-
fold compared to PAO1), this strain was susceptible to both car-
bapenems (MICs of imipenem and meropenem, 2 mg/liter and 4
mg/liter). Isolate SPME 205 was susceptible to imipenem (MIC, 2
FIG 2 Multiple sequence alignment by ClustalW of the OprD from PAO1 and clinical isolates belonging to different porin types. OprD sequences from strains
PA14, MFY72, LESB58, PA7, 59, and 120 are also included in the alignment. The OprD secondary structure was compared with that of 2ODJ (3) and visualized
by using ESPript 2.0 software. Characters on a white background indicate the amino acid substitutions compared to PAO1 OprD. Locations of ß-sheets are
indicated with black arrows. The open box shows the stretch of 12 amino acids from residues 372 to 383 located in loop L15 of OprD from isolates of types T1-VI,
T1-VIa, and T1-VII, which is replaced by the 10 amino acid residues 372(VDSSSS-YAGL-)384.
FIG 3 Tridimensional structure of PAO1OprD based on themodel by Biswas
et al. (3). (A) Approximate location of mutation G312R (in dark gray) between
ß-sheets 16 and 18 from OprD of isolate SPME 211 (type T3). (B) Location of
the Asp 43 residue (represented by black balls), replaced by an Asn in isolates
SPME 100 (type T1-IIa) and SPME 31 (type T1-VIa). (C andD) Shortening of
transmembrane strand 22 (in black) (C) compared to that of PAO1OprD (D).
This was due to a deletion of 10 amino acids from residue 434 in isolates SPME
211, SPME 137, and SPME 259 from OprD type T3.
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mg/liter) and intermediately susceptible to meropenem, probably
due to overexpression of MexB (10.3-fold compared to PAO1). Cu-
riously, the OMP analysis proved that this isolate did not produce
OprD,whichwas consistentwith the reduced oprD expression (0.16-
fold) as assessed by RT-PCR. The presence of the additional variable
sequenceof aminoacid residuesdoesnot appear tobecorrelatedwith
the loss of porin or with reduced susceptibility to carbapenems, as it
can be found in susceptible isolates that express OprD. The oprD
mRNAexpressionwasalsoassessed in16other isolates representative
of the different OprDT1 subtypes (see Fig. 4; see also Table S1 in the
supplemental material). Four isolates (SPME 33 [T1-Ia], SPME 39
[T1-IVb], SPME133 [T1-VI], andSPME206 [T1-VIb])were consid-
ered tohave reduced oprD expression (60%of that ofPAO1).Most
of the 16 isolates were susceptible to both carbapenems, with MICs
ranging from 0.12 to 2 mg/liter, with the exception of strain SPME
205 which was intermediately susceptible to meropenem (MIC of 8
mg/liter) (see Fig. 4).
The OprD “deficient types” (T2 and T3) included 20 strains
showing an earlier termination of translation due to premature
stop codons and frameshift mutations caused by nucleotide inser-
tions or deletions in the oprD structural gene. OprD type T2 was
found in 3 isolates (5%), two of them (SPME 102 and SPME 135)
susceptible to both carbapenems (MICs of imipenem ranging
from 1 to 4 mg/liter and of meropenem from 0.5 to 2 mg/liter),
showing a single-base G¡T substitution at nucleotide (nt) 180.
The remaining isolate (SPME 22) was susceptible to imipenem
(MIC, 4 mg/liter) and intermediately susceptible to meropenem
and presented a single-base C¡T substitution at nt 424 (Table 3;
see also Table S1 in the supplemental material).
OprD type T3 was found in 17 isolates (28%) showing different
profiles of susceptibility to both carbapenems, with MICs of imi-
penem ranging from 1 to 8mg/liter and ofmeropenem from 0.06 to
8mg/liter (Tables 2 and 3). The majority of mutations found within
this OprD type consisted of single nucleotide insertions at different
positions in the oprD gene. Most of the isolates harboring these mu-
tations were intermediately susceptible to imipenem and susceptible
tomeropenem (Table 3). The insertion of a C at nt 939 was themost
frequent mutation, observed in 6 of the 17 isolates; 4 of them were
susceptible to both carbapenems, and the 2 remainingwere interme-
diately susceptible to imipenem and susceptible to meropenem.
Isolates SPME 137 and SPME 211 presented a deletion of a T at
position 1295, and isolate SPME 259 showed a deletion of a C at
position 1297. Such deletions generated a TGA stop codon at po-
sition 1301. Earlier termination of OprD translation in these iso-
lates would yield a smaller protein, lacking 10 amino acid residues
at the end of the C-terminal extreme from a leucine at position
FIG 4 Transcription levels of oprD, carbapenem susceptibility profiles, and expression of AmpC and MexB in a selection of clinical isolates of P. aeruginosa
belonging toOprD types T1 andT3. Increased or decreased expression of oprD in clinical isolates was compared to that of PAO1 oprD, whichwas assigned a value
of 1.0. MICs of imipenem (IMP) and meropenem (MPM) are shown below the bars. Changes in AmpC andMexB expression are also shown., upregulation;
, no significant changes.
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434. Isolates SPME 137 and SPME 211 had reduced transcription
levels of oprD (0.27 and 0.13 of PAO1), whereas isolate SPME 259
showed levels of oprDmRNA similar to that of PAO1 (1.41-fold).
Isolates SPME 259 and SPME 137 were susceptible to both car-
bapenems (MICs of imipenem and meropenem, 1 and 1 mg/liter
and 4 and 2 mg/liter, respectively). Isolate SPME 211 was inter-
mediately susceptible to imipenemand susceptible tomeropenem
(MIC, 1 mg/liter) and also presented several amino acid substitu-
tions inOprD, including the divergent sequence of 10 amino acids
shortening the L15 loop. The replacement of a glycine by the basic
amino acid arginine (G312R) (Fig. 3A), unique for this isolate, was
especially interesting. This residue is located in a disordered loop
that is not observed in the OprD structure, but according to the
location of the last ordered residues of the loop, this glycine would
be located toward the center of the pore, between transmembrane
strands 16 and 18 (Fig. 3). Therefore, changes in the sequence of
this loopmay affect, though slightly, passing of imipenem through
the OprD pore, which could explain the differences in the suscep-
tibility profiles for imipenem in this isolate.
Another interesting finding within the OprD T3 group was the
presence of an isolate (SPME 66) with an insertion of a G at posi-
tion 23, leading to a frameshift mutation with a stop codon at
position 48. Curiously, the OMP profile analysis of this strain
showed expression of an OprD-like protein and the oprDmRNA
expression was very similar to that of PAO1 (1.26-fold) (Fig. 4; see
alsoTable S1 in the supplementalmaterial). Further analysis of the
oprD nucleotide sequence led us to think of a possible alternative
start codon (GTG) located 64 nucleotides downstream of the
usual PAO1 OprD start codon. This OprD allelic variant would
have a deletion of 21 amino acid residues at the beginning of the
N-terminal extreme (Fig. 2) and would also display some of the
mutations mentioned above and a tail of 57 additional residues at
the C-terminal extreme (Table 3) due to the insertion in oprD of
an A between nt 1316 and 1317, leading to a frameshift mutation
that affected the stop codon (TGA). Isolate SPME 66 had an imi-
penem MIC of 8 mg/liter and was susceptible to meropenem
(MIC, 1 mg/liter). Among the 20 isolates belonging to OprD-
deficient types, only 4 isolates had increased ampC expression, and
one was considered to have borderline incrase in expression (5.2-
fold compared to PAO1). The 15 remaining isolates did not show
significant expression of this enzyme (mRNA levels more than
5-fold lower than those of PAO1).
The mexT regulator gene that positively regulates the mexEF-
oprN multidrug efflux system was sequenced in 9 isolates, of
which 3 showed increased levels of expression of mexF, 4 were
considered to have borderline increase in expression (5- to 10-fold
compared to PAO1), and the remaining 2 did not have significant
mexT mRNA expression levels. The sequence of the mexT gene
obtained from the clinical isolates was compared to that of PAO1.
A deletion of 8 nt (GCCGGCCA) at position 240 of mexT was
found in all the isolates belonging to different OprD types and
showing carbapenem resistance profiles from intermediately sus-
ceptible to susceptible to both agents. This 8-bp deletion was
within a 14-bp direct repeat. A similar deletion in different P.
aeruginosa strains showing the so-called nfxC phenotype was pre-
viously described (22). Those authors demonstrated that the de-
letion of the 8 bp produces an active mexT. In a recent work, the
role ofMexT inMexEF-OprNupregulationwas also assessed in 10
nfxC mutants harboring the aforementioned 8-bp deletion, re-
sulting in reversion of the nonsense mexT gene. Such mutants
showed reduced mexT expression compared to the wild-type
strains (21) In our strains, this mutation in mexT was found in
strains showing either basal or increased activity of MexF. Several
other mutations were found in the mexT gene of the clinical iso-
lates (Table 4). Jin et al. compared themexT genes of two labora-
tory strains, PAO1 and PAK (15). The PAKMexTwas found to be
a peptide of 304 amino acid residues, in contrast to the 347-ami-
no-acid-long protein of PAO1MexT. According to those authors,
the start codon of the active mexT would be the ATG at position
122 (compared to the PAO1 mexT). Six of the 9 clinical isolates
showed a MexT sequence identical to that of strains PAK, PA14,
and 59 (Fig. 5). Isolate SPME 152 differed from the rest of the
isolates in a glycine residue replaced by a serine at position 300,
TABLE 4 Analysis of MexT in a selection of clinical isolates of
Pseudomonas aeruginosa
Strain
SPME
no.
Resistance
phenotypea mexTmutationsb
MexT amino
acid
substitution(s)c
Expression
of MexFd
22 IS-MIS 178C¡T, 321G¡A,
514T¡A, 622C623
DS-K208Q 
68 IIS-MS 178C¡T, 372T¡C,
393T¡C,
514T¡A,
702T¡C,
765G¡A,
771A¡G,
837G¡C,
921A¡G,
936G¡C,
957T¡C,
981T¡C,
987C¡G
F172I 
71 IS-MS 19A¡G, 514T¡A,
936G¡C
F172I 
82 IS-MS 178C¡T, 321G¡A,
472
T¡C
501G¡A,
514T¡A
F172I 
84 IS-MS 178C¡T, 321G¡A,
514T¡A
F172I 
149 IS-MS 514T¡A, 629A630,
936G¡C,
898G¡A
DS-T211D 
152 IIS-MIS 514T¡A, 898G¡A,
936G¡C
F172I, G300S 
205 IS-MIS 321G¡A, 472T¡C,
501G¡A,
514T¡A
F172I 
257 IS-MS 444C¡G, 514T¡A F172I 
a I, imipenem; M, meropenem; S, susceptible; IS, intermediately susceptible.
b Compared to the PAO1mexT.
c Compared to the PAO1 MexT. The N-terminal sequences of MexT from strains PAK
and PA14 and the clinical isolates differ from the PAO1 MexT sequence in the first 78
amino acid residues MNRND[3]LR[11]RVD[5]LNLLIVFETLMHER[24]SVTRAAE
KLFL (see Fig. 5). Accordingly, themexT translation would start from the ATG at
position 122, generating a 304-amino-acid-long peptide (except for the MexT of SPME
22 and SPME 149, which is 336 amino acids long). DS, divergent sequence starting with
the replacement of a lysine (K) by a glutamine (Q) at position 208 in MexT of isolate
SPME 22 and a threonine (T) by an aspartate (D) at position 211 in MexT of isolate
SPME 149.
d, overexpression;, borderline increase in expression;, no significant
expression.
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taking as a reference the PAO1 MexT. All of these MexT variants
kept a conserved domain of the LysR family transcriptional factors
from residues 144 to 340 (Fig. 5). The MexT of isolates SPME 22
and SPME 149 had a 336-amino-acid peptide that resulted from a
frameshift mutation caused by a nucleotide insertion in themexT
gene at positions 622 and 629, respectively (Table 4). TheMexT in
these isolates differed from the rest of the isolates in the C-termi-
nal extreme from residue 208 in isolate SPME 22 and residue 211
in SPME 149 (Fig. 5). Despite the similarity (98%) of the MexT
sequences from these two isolates (data not shown), the mRNA
levels ofmexF in isolate SPME 149 were not significant (see Table
S1 in the supplemental material). Similar results were found for
the rest of clinical isolates, showing identicalMexT sequences (ex-
cept for the SPME 152 MexT, with 99% similarity). A possible
explanation for the basal levels of MexF displayed by some of the
clinical strains with an active mexT is the presence of a second
active regulatory protein, MexS, that was previously shown to re-
press the activity of MexEF-OprN (40). Llanes et al. also assessed
the impact of mutations inmexS andmvaT, an additional regula-
tory protein, on the activity of MexEF-OprN, but their contribu-
tion to the nfxC resistance phenotype is something that has to be
further investigated (21).
Conclusions. Mutations in oprD caused by nucleotide inser-
tions or deletions in the oprD structural gene have been found to
be the major mechanisms leading to inactivation of OprD with
concomitant loss of the porin from P. aeruginosa outer mem-
branes and increases of theMICs of carbapenems. In this study,we
have identified a group of clinical isolates of P. aeruginosa with
distinctive carbapenem resistance phenotypes that confront the
previous theories of OprD regulation. The alterations and muta-
tions of OprD found in such strains did not always explain the
levels of susceptibility to carbapenems. We found that OprD in-
activating mutations in clinical strains of P. aeruginosa are not
confined only to carbapenem-resistant isolates but can also be
present in susceptible strains with MICs of imipenem or mero-
penem of only 0.06 to 4 mg/liter. We believe that the actual con-
tribution of OprD alterations to the resistance of P. aeruginosa has
not yet been completely defined, as OprD deficiency does not
always result in an increase of the MICs above the susceptible
breakpoints.
ACKNOWLEDGMENTS
We are grateful to all clinical microbiologists and infectious disease spe-
cialists involved in this project from Hospital Universitario de Bellvitge
(Barcelona, Spain), Consorsi Sanitari Parc Tauli (Barcelona, Spain), Hos-
pitalUniversitarioVirgen de laMacarena (Sevilla, Spain),Hospital Vall de
Hebrón (Barcelona, Spain), Hospital Universitari Son Dureta (Palma de
Mallorca, Spain), Hospital de Sant Pau (Barcelona, Spain), Hospital Uni-
versitario Marqués de Valdecilla (Santander, Spain), Hospital Virgen del
Rocío (Sevilla, Spain), Hospital Reina Sofía (Córdoba, Spain), and Hos-
pital Mutua de Tarrasa (Barcelona, Spain). We thank Bert van Den Berg
for helpful comments on the PAO1 OprD structure.
This work was supported by theMinisterio de Ciencia e Innovación of
Spain and Instituto de Salud Carlos III, through the Spanish Network for
the Research in Infectious Diseases (REIPI C03/14 and RD06/0008), and
grants PI08/0802, PS09/00033, and PI08/0276.
REFERENCES
1. Aires JR, Köhler T, Nikaido H, Plesiat P. 1999. Involvement of an active
efflux system in the natural resistance of Pseudomonas aeruginosa to ami-
noglycosides. Antimicrob. Agents Chemother. 43:2624–2628.
2. Bellido F, Veuthey C, Blaser J, Bauernfeind A, Pechère JC. 1990. Novel
FIG 5 Multiple sequence alignment by ClustalW of MexT from PAO1 and
clinical isolates of P. aeruginosa analyzed in this study. The MexT sequences
from strains PAK, PA14, and 59 are also included. Amino acid residue differ-
ences compared to PAO1 MexT are in bold characters. The C-terminal sub-
strate-binding domain of the LysR-type transcriptional regulator is high-
lighted by gray shading.
Ocampo-Sosa et al.
1712 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 19, 2013 by Red de Bibliotecas del CSIC
http://aac.asm
.org/
D
ow
nloaded from
 
resistance to imipenem associatedwith an altered PBP-4 in aPseudomonas
aeruginosa clinical isolate. J. Antimicrob. Chemother. 25:57–68.
3. Biswas S, Mohammad MM, Patel DR, Movileanu L, van den Berg B.
2007. Structural insight into OprD substrate specificity. Nat. Struct. Mol.
Biol. 14:1108–1109.
4. Cabot G, et al. 2011. Overexpression of AmpC and efflux pumps in P.
aeruginosa from blood stream infections: prevalence and linkage to resis-
tance in a Spanish multicenter study. Antimicrob. Agents Chemother.
55:1906–1911.
5. Clinical and Laboratory Standards Institute (CLSI). 2011. Performance
standards for antimicrobial susceptibility testing, vol 31, no 1, 20th infor-
mational supplement M100-S20. CLSI, Wayne, PA.
6. Dib C, Trias DC, Jarlier V. 1995. Lack of additive effect between mech-
anisms of resistance to carbapenems and other beta-lactam agents inPseu-
domonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 14:979–986.
7. Dumas JL, van Delden C, Perron K, Köhler T. 2006. Analysis of anti-
biotic resistance gene expresión in Pseudomonas aeruginosa by quantita-
tive real-time PCR. FEMS Microbiol. Lett. 254:217–225.
8. El Amin N, et al. 2005. Carbapenem resistance mechanisms in Pseudomo-
nas aeruginosa: alterations of porin OprD and efflux proteins do not fully
explain resistance patterns observed in clinical isolates. APMIS 113:187–
196.
9. Epp SF, et al. 2001. C-terminal region of Pseudomonas aeruginosa outer
membrane porin OprD modulates susceptibility to meropenem. Antimi-
crob. Agents Chemother. 45:1780–1787.
10. Farra A, Islam S, Strålfors A, Sörberg M, Wretlind B. 2008. Role of outer
membrane protein OprD and penicillin-binding proteins in resistance of
Pseudomonas aeruginosa to imipenem and meropenem. Int. J. Antimi-
crob. Agents 31:427–433.
11. Gutiérrez O, et al. 2007. Molecular epidemiology and mechanisms of
carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish
hospitals. Antimicrob. Agents Chemother. 51:4329–4335.
12. Hancock REW, Speert DP. 2000. Antibiotic resistance in Pseudomonas
aeruginosa: mechanisms and impact on treatment. Drug Resist. Updat.
3:247–255.
13. Hashizume T, Ishino F, Nakagawa J, Tamaki S, Matsuhashi M. 1984.
Studies on the mechanism of action of imipenem (N-formimidoylthiena-
mycin) in vitro: binding to the penicillin binding proteins (PBPs) in Esch-
erichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activi-
ties due to the PBPs in E. coli. J. Antibiot. 37:394–400.
14. Huang H, Jeanteur D, Pattus F, Hancock RE. 1995. Membrane topology
and site-specific mutagenesis of Pseudomonas aeruginosa porin OprD.
Mol. Microbiol. 16:931–941.
15. Jin Y, Yang H, Qiao M, Jin S. 2011. MexT regulates the type III secretion
system through MexS and PtrC in Pseudomonas aeruginosa. J. Bacteriol.
193:399–410.
16. Köhler T, Michéa-Hamzehpour M, Epp SF, Pechère JC. 1999. Carbap-
enem activities against Pseudomonas aeruginosa: respective contributions
ofOprD and efflux systems. Antimicrob. Agents Chemother. 43:424–427.
17. Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of
MexT, the regulator of the MexE-MexF-OprNmultidrug efflux system of
Pseudomonas aeruginosa. J. Bacteriol. 181:6300–6305.
18. Lauretti L, et al. 1999. Cloning and characterization of blaVIM, a new
integron-bornemetallo--lactamase gene fromaPseudomonas aeruginosa
clinical isolate. Antimicrob. Agents Chemother. 43:1584–1590.
19. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseu-
domonas aeruginosa: clinical impact and complex regulation of chromo-
somally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582–
616.
20. Livermore DM. 2002.Multiplemechanisms of antimicrobial resistance in
Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634–
640.
21. Llanes C, et al. 2011. Role of the MexEF-OprN efflux system in low-level
resistance of Pseudomonas aeruginosa to ciprofloxacin. Antimicrob.
Agents Chemother. 55:5676–5684. doi:10.1128/AAC.00101-11.
22. Maseda H, Saito K, Nakajima A, Nakae T. 2000. Variation of the mexT
gene, a regulator of theMexEF-OprN efflux pump expression inwild-type
strains of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 192:107–112.
23. Masuda N, et al. 2000. Contribution of the MexX-MexY-OprM efflux
system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob.
Agents Chemother. 44:2242–2246.
24. Masuda N, et al. 2000. Substrate specificities of MexAB-OprM, MexCD-
OprJ, and MexXYOprM efflux pumps in Pseudomonas aeruginosa. Anti-
microb. Agents Chemother. 44:3322–3327.
25. Mc Cay PH, Ocampo-Sosa AA, Fleming GT. 2010. Effect of subinhibi-
tory concentrations of benzalkonium chloride on the competitiveness of
Pseudomonas aeruginosa grown in continuous culture. Microbiology 156:
30–38.
26. Mushtaq S, Ge Y, Livermore DM. 2004. Doripenem versus Pseudomonas
aeruginosa in vitro: activity against characterized isolates, mutants, and
transconjugants and resistance selection potential. Antimicrob. Agents
Chemother. 48:3086–3092.
27. Nikaido H. 1994. Prevention of drug access to bacterial targets: permea-
bility barriers and active efflux. Science 264:382–388.
28. Obritsch MD, Fish DN, MacLaren R, Jung R. 2004. National surveil-
lance of antimicrobial resistance in Pseudomonas aeruginosa isolates ob-
tained from intensive care unit patients from 1993 to 2002. Antimicrob.
Agents Chemother. 48:4606–4610.
29. Pérez FJ, Gimeno C, Navarro D, García-de-Lomas J. 1996. Meropenem
permeation through the outer membrane of Pseudomonas aeruginosa can
involve pathways other than the OprD porin channel. Chemotherapy 42:
210–214.
30. Pirnay JP, et al. 2002. Analysis of the Pseudomonas aeruginosa oprD gene
from clinical and environmental isolates. Environ. Microbiol. 4:872–882.
31. Poirel L, et al. 2000. Characterization of VIM-2, a carbapenem-
hydrolyzing metallo--lactamase and its plasmid- and integron-borne
gene from a Pseudomonas aeruginosa clinical isolate in France. Antimi-
crob. Agents Chemother. 44:891–897.
32. Poole K. 2004. Efflux-mediated multiresistance in Gram-negative bacte-
ria. Clin. Microbiol. Infect. 10:12–26.
33. Poole K. 2004. Efflux pumps, p 635–674. In Ramos J-L (ed), Pseudomo-
nas: genomics, life style and molecular architecture, vol 1. Kluwer Aca-
demic/Plenum Publishers, New York, NY.
34. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system,
ampC, and oprD expression in carbapenem resistance of Pseudomonas
aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633–
1641.
35. Riera E, et al. 2011. Pseudomonas aeruginosa carbapenem resistance
mechanisms in Spain: impact on the activity of imipenem, meropenem
and doripenem. J. Antimicrob. Chemother. 66:2022–2027. doi:10.1093/
jac/dkr232.
36. Rodríguez MC, et al. 2010. Molecular characterization of Pseudomonas
aeruginosa isolates in Cantabria, Spain, producing VIM-2 metallo-beta-
lactamase. Enferm. Infecc. Microbiol. Clin. 28:99–103. (In Spanish.)
37. Rodríguez-Martínez JM, Poirel L, Nordmann P. 2009. Molecular epi-
demiology and mechanisms of carbapenem resistance in Pseudomonas
aeruginosa. Antimicrob. Agents Chemother. 53:4783–4788.
38. Römling U, Tümmler B. 2000. Achieving 100% typeability of Pseudomo-
nas aeruginosa by pulsed-field gel electrophoresis. J. Clin. Microbiol. 38:
464–465.
39. Sanbongi Y, et al. 2009. Classification of OprD sequence and correlation
with antimicrobial activity of carbapenem agents in Pseudomonas aerugi-
nosa clinical isolates collected in Japan.Microbiol. Immunol. 53:361–367.
40. Sobel ML, Neshat S, Poole K. 2005. Mutations in PA2491 (mexS) pro-
mote MexT-dependentmexEF-oprN expression andmultidrug resistance
in a clinical strain ofPseudomonas aeruginosa. J. Bacteriol. 187:1246–1253.
41. Tenover FC, et al. 1995. Interpreting chromosomal DNA restriction
patterns produced by pulsed-field gel electrophoresis: criteria for bacterial
strain typing. J. Clin. Microbiol. 33:2233–2239.
42. Trias J, Nikaido H. 1990. Outer membrane protein D2 catalyzes facili-
tated diffusion of carbapenem and penems through the outer membrane
of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:52–57.
43. Wolter DJ, Hanson ND, Lister PD. 2004. Insertional inactivation of oprD
in clinical isolates of Pseudomonas aeruginosa leading to carbapenem re-
sistance. FEMS Microbiol. Lett. 236:137–143.
44. Wolter DJ, Smith-Moland E, Goering RV, Hanson ND, Lister PD. 2004.
Multidrug resistance associated withmexXY expression in clinical isolates
of Pseudomonas aeruginosa from a Texas hospital. Diagn. Microbiol. In-
fect. Dis. 50:43–50.
45. Yang Y, Bhachech N, Bush K. 1995. Biochemical comparison of imi-
penem, meropenem and biapenem: permeability, binding to penicillin-
binding proteins, and stability to hydrolysis by beta-lactamases. J. Antimi-
crob. Chemother. 35:75–84.
P. aeruginosa OprD in Carbapenem-Nonresistant Strains
April 2012 Volume 56 Number 4 aac.asm.org 1713
 o
n
 D
ecem
ber 19, 2013 by Red de Bibliotecas del CSIC
http://aac.asm
.org/
D
ow
nloaded from
 
